This study is evaluating whether a drug used to treat breast cancer can be used to treat breast cancer in people with early stage breast cancer.
3 Primary · 27 Secondary · Reporting Duration: Median follow-up was 3.9 years. The AE data cutoff date is 21 April 2020.
Active Control
512 Total Participants · 4 Treatment Groups
Primary Treatment: Trastuzumab emtansine (T-DM1) · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: